Literature DB >> 15323151

ACE inhibitors and target organ protection. An expanded role for these antihypertensive agents?

Robert D Toto1, Steven Rinner, C Venkata S Ram.   

Abstract

Lowering the risk of cardiovascular disease (CVD) involves more than treatment of individual risk factors such as hypertension, diabetes, and chronic kidney disease. In this article, Drs Toto, Rinner, and Ram present an evidence-based approach to reducing CVD risk and suggest that optimal treatment with angiotensin-converting enzyme (ACE) inhibitors should be extended to a larger proportion of at-risk patients and in particular to those not previously considered candidates for use of these agents.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15323151     DOI: 10.3810/pgm.2004.08.1567

Source DB:  PubMed          Journal:  Postgrad Med        ISSN: 0032-5481            Impact factor:   3.840


  4 in total

1.  Irbesartan/HCTZ fixed combinations in patients of different racial/ethnic groups with uncontrolled systolic blood pressure on monotherapy.

Authors:  Elizabeth O Ofili; Keith C Ferdinand; Elijah Saunders; Joel M Neutel; George L Bakris; William C Cushman; James R Sowers; Michael A Weber
Journal:  J Natl Med Assoc       Date:  2006-04       Impact factor: 1.798

Review 2.  Zofenopril plus hydrochlorothiazide: Combination therapy for the treatment of mild to moderate hypertension.

Authors:  Alberto Zanchetti; Gianfranco Parati; Ettore Malacco
Journal:  Drugs       Date:  2006       Impact factor: 9.546

Review 3.  Complex Relationship Between Cardiac Fibroblasts and Cardiomyocytes in Health and Disease.

Authors:  Caitlin Hall; Katja Gehmlich; Chris Denning; Davor Pavlovic
Journal:  J Am Heart Assoc       Date:  2021-02-15       Impact factor: 5.501

Review 4.  Fixed combination of zofenopril plus hydrochlorothiazide in the management of hypertension: a review of available data.

Authors:  Claudio Borghi; Arrigo F G Cicero
Journal:  Vasc Health Risk Manag       Date:  2006
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.